MSLN, FGFBP1, ICOSLG, and TIE2 were also elevated in sera from patients with BPH, suggesting that MSLN, FGFBP1, ICOSLG, and TIE2 were not specific for high-risk prostate cancer. This evidence concerns the gene FGFBP1 and prostate carcinoma.